Regulation & Compliance
10 cited notes for compounding pharmacy owners.
Accreditation and Credentials in Pharmacy Marketing, Explained
How third-party accreditation, state licensure, and other verifiable credentials work as trust signals in compounding pharmacy marketing, what they do and do not let you claim, and why you should only reference one if you actually hold it. Educational only, not legal advice.
7 min →Regulation & ComplianceTelehealth Rules and Pharmacy Marketing, Explained
How telehealth rules, including expectations around a real prescriber evaluation and FTC enforcement against deceptive telehealth marketing, shape what pharmacies and partner clinics can claim in advertising. Educational only, not legal advice.
8 min →Regulation & ComplianceQuality Assurance in Compounding, Explained
A plain-English overview of the quality framework behind compounding, including USP chapters <795>, <797>, and <800>, beyond-use dating, and testing, and how to reference that framework honestly in marketing without overclaiming. Educational only.
9 min →Regulation & ComplianceAnti-Kickback Pitfalls in Pharmacy Marketing
A careful, plain-English overview of how the federal Anti-Kickback Statute and state fee-splitting rules can touch pharmacy marketing arrangements, including volume-based pay and referral fees. Educational only, not legal advice. Verify with counsel.
9 min →Regulation & ComplianceLegitScript Certification and Pharmacy Ads, Explained
What LegitScript certification is, when ad platforms like Google and Meta require it for pharmacy advertising, and why it is per-pharmacy and held by the pharmacy, not by an agency. Educational only, not legal advice.
8 min →Regulation & ComplianceMeta Ads Compliance for Compounding Pharmacies, Explained
A plain-English summary of how Meta's advertising policies apply to compounding-pharmacy ads, the education and business-to-business lane, why landing pages get reviewed too, and the triggers that lead to rejection. Educational only, not legal advice.
9 min →Regulation & ComplianceThe GLP-1 Regulatory Picture and Compounding, in 2026
A neutral, regulation-only summary of how shortage-list dynamics and the 503A and 503B frameworks shape the conversation around GLP-1 medicines and compounding. No clinical or availability claims. This area changes fast, so verify against the FDA.
8 min →Regulation & ComplianceFDA Bulk Drug Substances Lists for 503A and 503B, Explained
The FDA maintains lists that address which bulk drug substances may be used in compounding under sections 503A and 503B. Here is what the lists are, how nomination and categories work, and why this area keeps changing.
8 min →Regulation & ComplianceUSP <797> Sterile Compounding: A Plain-English Overview
USP General Chapter <797> sets standards for compounding sterile preparations, covering personnel practices, the compounding environment, and beyond-use dating. Here is an honest, plain-English overview of what it covers and why it matters.
8 min →Regulation & Compliance503A vs 503B Compounding, Explained
A 503A pharmacy compounds for an identified patient under a prescription and is overseen mainly by state boards. A 503B outsourcing facility can compound larger batches under FDA oversight and cGMP. Here is the clear comparison.
8 min →